Scribe Therapeutics Inc. Common Stock (SCTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scribe Therapeutics Inc. Common Stock (SCTX) has a cash flow conversion efficiency ratio of 0.048x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.55 Million) by net assets ($-158.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View SCTX share price today for real-time trading data and today's change.
Scribe Therapeutics Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Scribe Therapeutics Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Scribe Therapeutics Inc. Common Stock (SCTX) total market value for the company's overall valuation and market capitalisation.
Scribe Therapeutics Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scribe Therapeutics Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Scribe Therapeutics Inc. Common Stock balance sheet assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LPKF Laser & Electronics AG
F:LPK
|
-0.091x |
|
Shandong Hiking International Co Ltd Class A
SHG:600735
|
0.012x |
|
Dipula Income Fund Ltd
JSE:DIB
|
0.021x |
|
Grand Korea Leisure Co. Ltd
KO:114090
|
0.012x |
|
Shui On Land Limited
F:OL5
|
0.011x |
|
Beijing HuaYuanYiTong Thermal Technology Co Ltd
SHE:002893
|
0.076x |
|
Tubacex S.A
MC:TUB
|
0.044x |
|
Wenfeng Great World Chain Development Corp
SHG:601010
|
0.020x |
Annual Cash Flow Conversion Efficiency for Scribe Therapeutics Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Scribe Therapeutics Inc. Common Stock from 2024 to 2025. Review Scribe Therapeutics Inc. Common Stock free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-143.42 Million | $-45.21 Million | 0.315x | -12.29% |
| 2024-12-31 | $-125.86 Million | $-45.23 Million | 0.359x | -- |
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200… Read more